will crypto- Top searches

Zhonglu Co., Ltd.: The total amount of taxes and late fees paid is 15,430,100 yuan. Zhonglu Co., Ltd. announced that the company, as a limited partner of Zhonglu Advantage, received its cash asset distribution according to the resolution of Zhonglu Advantage Partner Meeting. In view of the above-mentioned asset allocation matters, the company strictly abides by the relevant regulations and adopts the principle of "tax after distribution". As required, it has declared and paid enterprise income tax of 11,770,500 yuan and late payment fee of 3,659,500 yuan, totaling 15,430,100 yuan. The late payment fee paid by the company will be included in the current profit and loss in 2024, which is expected to affect the company's net profit attributable to shareholders of listed companies in 2024 by about 3,659,500 yuan.FTSE China A50 index futures fell 2%.On the 13th, caustic soda dropped by 3.03%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract caustic soda 2501 closed, with a turnover of 57,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 1,383 lots. The total contract turnover of caustic soda futures was 94,800 lots, an increase of 27,900 lots over the previous day. The first 20 seats in the contract held 71,100 lots, an increase of 2,202 lots over the previous day. Short positions in the top 20 seats of the contract were 72,700 lots, an increase of 1,157 lots over the previous day. (Sina Futures)

Stock index futures continued to fall, and the main contract of SSE 50 Stock Index Futures (IH) fell by 2.00% in the day, and now it is reported at 2,653.6 points. The main contract of CSI 500 stock index futures (IC) fell by 2.00% in the day and is now reported at 5976.8 points.Six residential plots in Wuhan received 5.457 billion yuan: OCT received 2.42 billion yuan from Yangchun Lake. According to the monitoring of the China Central Finger Research Institute, on December 13th, Wuhan successfully sold six residential plots, including Hanyang District, Donghu High-tech Zone, Hongshan District, huangpi district District and Qingshan District. The total land area of 6 plots is 214,964 ㎡, the total planned construction area is 726,285.4 ㎡, and the total starting price is 5.457 billion yuan. In the end, all six plots were sold at the reserve price, with a total income of 5.457 billion yuan, including Yangchun Lake in Hongshan District, OCT, and Hanyang District, Wuhan Huijing Real Estate, a private enterprise.To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)

Namibia's GDP in the third quarter increased by 2.8% year on year.US Secretary of State Blinken: discussed the ceasefire in Gaza with Turkish Foreign Minister Fidan. Blinken: All parties reached a broad consensus on what we want to see in Syria. We discussed the necessity of continuing efforts to crack down on the extremist organization "Islamic State". We have seen encouraging signs in the past few weeks that a ceasefire in Gaza is possible.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.